Study of MET233 and MET097 for Obesity or Overweight
This study is testing the safety and how well two medications, MET233 and MET097, work together to treat adults who are overweight or have obesity. Some participants in the study may also have type 2 diabetes. Researchers are looking for any side effects (adverse events) that might happen when people take these medications. You might be able to join if you are between 18 and 75 years old and have a Body Mass Index (BMI) between 27.0 and 45.0 kg/m2. The study is currently recruiting 381 participants, but its overall status is unclear.
- Study design
- This is a randomized, placebo-controlled, double-blind study, meaning some participants will receive the active drugs and others a placebo (inactive substance), and neither you nor your doctor will know which you are receiving. The study aims to enroll 381 participants.
- What's involved
- After a screening period of up to 4 weeks, you would receive either a single dose or weekly/monthly doses of the study medications or placebo. The duration of dosing varies by part of the study, lasting up to 12 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for safety for approximately 11 to 12 weeks after your last dose, depending on which part of the study you are in.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06924320
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Recruiting
PHASE1Ages 18–75InterventionalTreatmentPfizer
~381 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:MET233 and MET097PlaceboMET097
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of treatment-emergent adverse events (TEAEs)
Measured over Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adult males or females aged 18 to 75 years (inclusive) at the time of screening.
BMI ≥27.0 kg/m2 and ≤38.0 kg/m2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts G.
Participants must be in generally stable health, as determined by the investigator based on medical history, physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).
Participants must have no clinically significant diseases or clinically significant findings on the physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).
Participants in Parts C must not have clinically significant diseases except type 2 diabetes mellitus (T2DM), sleep apnea, well-controlled hypertension, and/or dyslipidemia.
Participants in Parts E and G must not have any clinically significant diseases except hypertension, dyslipidemia, and/or a clinical diagnosis of sleep apnea.
Willing and able to comply with all scheduled study visits, procedures, and required assessments.
Women of childbearing potential must be willing to comply with protocol-specified contraceptive requirements and must not plan to become pregnant during the study.
Exclusion
Female who is lactating or who is pregnant according to the pregnancy test at Screening or on Day 1. Unwillingness or inability to comply with protocol-specified contraceptive requirements.
Clinically significant abnormalities in laboratory results in the opinion of the investigator, increase risk or interfere with study participation.
Seated blood pressure higher than 160/100 mmHg at the Screening visit or prior to the first study drug administration.
Elevated resting pulse greater than 100 beats per minute at Screening visit or prior to the first study drug administration.
Estimated glomerular filtration rate (eGFR) \<80 mL/min at the Screening visit.
Diagnosis of Type 1 diabetes.
For Part A, Part B, Part D, Part E and Part G: Diagnosis of T2DM or glycated hemoglobin (HbA1c) \> 6.4% or fasting plasma glucose \>126 mg/dL at the Screening visit or history of taking any medications to lower glucose.
For Part A, Part B and Part D: Participant reported weight-related comorbidity, including sleep apnea and cardiovascular disease.
Use of prohibited prescription or non-prescription medications, supplements, or investigational products within protocol-defined washout periods.
History or presence of clinically significant gastrointestinal, endocrine, respiratory, renal, hepatic, hematologic, neurologic, cardiovascular, psychiatric, immunologic, or other systemic diseases, except where explicitly permitted by the protocol.
Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome, pancreatitis, or pancreatic cancer.
History of acute or chronic pancreatitis or pancreatic cancer.
Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration or plans to do so.
History of bariatric or weight-loss surgery.
Clinically significant psychiatric illness that may interfere with study participation or safety.
Screening assessments indicative of moderate to severe depression.
History of drug or alcohol abuse or dependence within the past 2 years.
What this trial measures
- Occurrence of treatment-emergent adverse events (TEAEs)Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)
For Part A, B, C, D, E and G